Xeris Biopharma Holdings Statistics
Total Valuation
XERS has a market cap or net worth of $1.32 billion. The enterprise value is $1.52 billion.
Important Dates
The next estimated earnings date is Friday, November 7, 2025, before market open.
| Earnings Date | Nov 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
XERS has 161.48 million shares outstanding. The number of shares has increased by 8.03% in one year.
| Current Share Class | 161.48M |
| Shares Outstanding | 161.48M |
| Shares Change (YoY) | +8.03% |
| Shares Change (QoQ) | +4.60% |
| Owned by Insiders (%) | 4.48% |
| Owned by Institutions (%) | 56.50% |
| Float | 154.25M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 57.73 |
| PS Ratio | 5.07 |
| Forward PS | 4.06 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.17 |
| EV / EBITDA | 181.23 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.95
| Current Ratio | 1.95 |
| Quick Ratio | 1.18 |
| Debt / Equity | n/a |
| Debt / EBITDA | 16.28 |
| Debt / FCF | n/a |
| Interest Coverage | -0.12 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -0.70% |
| Return on Invested Capital (ROIC) | -0.95% |
| Return on Capital Employed (ROCE) | -1.55% |
| Revenue Per Employee | $624,429 |
| Profits Per Employee | -$81,216 |
| Employee Count | 394 |
| Asset Turnover | 0.74 |
| Inventory Turnover | 0.79 |
Taxes
| Income Tax | -3.32M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +192.14% in the last 52 weeks. The beta is 0.91, so XERS's price volatility has been similar to the market average.
| Beta (5Y) | 0.91 |
| 52-Week Price Change | +192.14% |
| 50-Day Moving Average | 6.97 |
| 200-Day Moving Average | 4.95 |
| Relative Strength Index (RSI) | 62.12 |
| Average Volume (20 Days) | 1,981,608 |
Short Selling Information
The latest short interest is 16.24 million, so 10.06% of the outstanding shares have been sold short.
| Short Interest | 16.24M |
| Short Previous Month | 14.71M |
| Short % of Shares Out | 10.06% |
| Short % of Float | 10.53% |
| Short Ratio (days to cover) | 8.19 |
Income Statement
In the last 12 months, XERS had revenue of $246.03 million and -$32.00 million in losses. Loss per share was -$0.21.
| Revenue | 246.03M |
| Gross Profit | 202.33M |
| Operating Income | -3.72M |
| Pretax Income | -35.32M |
| Net Income | -32.00M |
| EBITDA | 8.38M |
| EBIT | -3.72M |
| Loss Per Share | -$0.21 |
Full Income StatementBalance Sheet
The company has $59.29 million in cash and $257.22 million in debt, giving a net cash position of -$197.94 million or -$1.23 per share.
| Cash & Cash Equivalents | 59.29M |
| Total Debt | 257.22M |
| Net Cash | -197.94M |
| Net Cash Per Share | -$1.23 |
| Equity (Book Value) | -19.30M |
| Book Value Per Share | -0.12 |
| Working Capital | 90.41M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$16.18 million and capital expenditures -$599,000, giving a free cash flow of -$16.78 million.
| Operating Cash Flow | -16.18M |
| Capital Expenditures | -599,000 |
| Free Cash Flow | -16.78M |
| FCF Per Share | -$0.10 |
Full Cash Flow StatementMargins
Gross margin is 82.24%, with operating and profit margins of -1.51% and -13.01%.
| Gross Margin | 82.24% |
| Operating Margin | -1.51% |
| Pretax Margin | -14.36% |
| Profit Margin | -13.01% |
| EBITDA Margin | 3.41% |
| EBIT Margin | -1.51% |
| FCF Margin | n/a |
Dividends & Yields
XERS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.03% |
| Shareholder Yield | -8.03% |
| Earnings Yield | -2.42% |
| FCF Yield | -1.27% |
Analyst Forecast
The average price target for XERS is $8.00, which is -2.20% lower than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.00 |
| Price Target Difference | -2.20% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 23.38% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
XERS has an Altman Z-Score of -0.91 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.91 |
| Piotroski F-Score | 3 |
